The use of anti-PD-1/PD-L1 ICIs with or without chemotherapy as post-surgery adjuvant therapy in NSCLC is under investigation, and no mature study result is available to date [78,102]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.